|Mrs. Kari Eian Krogstad||Chief Exec. Officer and Pres||2.68M||N/A||53|
|Mr. Thomas Jakobsen||Chief Financial Officer||N/A||N/A||48|
|Ms. Hæge Johanne Krogh Wetterhus||VP of Marketing||1.35M||N/A||53|
|Mr. Roger Reino Morberg||VP of Sales||1.61M||N/A||53|
|Mr. Ole Jargen Robsrud||Chief Exec. Officer of Medistim Norge AS and Managing Director of Medistim Norge AS||1.36M||N/A||N/A|
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the Unites States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; imaging probes to visualize blood flow; VeriQ C, a system that combines ultrasound imaging and proven TTFM in a single system for cardiovascular procedures; and VeriQ that offers proven TTFM and doppler velocity measurements for intraoperative blood flow and graft patency verification. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in a range of applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, the company distributes and sells third party products. Medistim ASA was founded in 1984 and is headquartered in Oslo, Norway.
Medistim ASA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.